In haematopoietic stem cell transplant (HSCT) recipients, cytomegalovirus (CMV) infection contributes significantly to morbidity and mortality in both the early and late post-transplant period. Ganciclovir (GCV) is the treatment of choice for CMV, but requires intravenous administration, a fact that complicates its long-term use. Oral valganciclovir (VGCV) and intravenous GCV were recently shown to have similar efficacy for pre-emptive CMV treatment in solid organ transplant recipients, but relatively limited data are available in HSCT recipients. The objectives of this study were to compare the efficacy of VGCV versus intravenous GCV or foscarnet (FOS) for pre-emptive therapy of active CMV infection in allogeneic HSCT and to determine the incidence of adverse effects and relapses.
Methods
This was a 2-year prospective, comparative cohort study in which 237 episodes of pre-emptive therapy for active CMV infection were collected in 166 allogeneic HSCT recipients out of 717 included in the Spanish Network for Research on Infection in Transplantation (RESITRA/REIPI) database. Intravenous GCV was the first-line treatment in 112 episodes, intravenous FOS in 38 episodes, and oral VGCV in 87 episodes.
Results
VGCV was used as pre-emptive therapy for active CMV infection in 87 episodes. Excluding episodes considered as relapse, VGCV was as successful (91.4% [74/81]) as GCV (83.7% [87/14]) or FOS (75.8% [25/33]). In the VGCV arm, 7 (8.6%) cases were considered treatment failures: 4 (4.9%) because of adverse events, 1 (1.2%) due to persistent viral activity and 2 (2.5%) based on clinical decision. There were also 6 (7.4%) cases of recurrent infection. No statistically significant differences were found when compared to GCV or FOS.
Conclusions
In allogeneic HSCT recipients, VGCV seemed effective and safe in the pre-emptive therapy of active CMV infection.
References
1.
BoeckhM., FishmanJ.A., RubinR.H.Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant2003; 9: 543–558.
2.
BjorklundA., AschanJ., LabopinM.Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation. Bone Marrow Transplant2007; 40: 1055–1062.
3.
NakamuraR., CortezK., SolomonS.High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant2002; 30: 235–242.
4.
RazonableR.R., EmeryV.C.Management of CMV infection and disease in transplant patients. 27-29 February 2004. Herpes2004; 11: 77–86.
5.
BoeckhM.Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy. Transpl Infect Dis1999; 1: 165–178.
6.
YanadaM., YamamotoK., EmiN.Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant2003; 32: 801–807.
7.
ZaiaJ.A.Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation. Clin Infect Dis2002; 35: 999–1004.
8.
LjungmanP., de la CamaraR., MilpiedN.Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood2002; 99: 3050–3056.
9.
BoeckhM., GooleyT.A., MyersonD., CunninghamT., SchochG., BowdenR.A.Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood1996; 88: 4063–4071.
10.
LjungmanP., de la CamaraR., CordonnierC.Management of CMV, HHV-6, HHV-7 and Kaposisarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant2008; 42: 227–240.
11.
BoeckhM., ZaiaJ.A., JungD., SkettinoS., ChaunceyT.R., BowdenR.A.A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation. Biol Blood Marrow Transplant1998; 4: 13–19.
12.
EinseleH., ReusserP., BornhäuserM.Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood2006; 107: 3002–3008.
13.
LimZ.Y., CookG., JohnsonP.R.Results of a phase I/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation. Leuk Res2009; 33: 244–249.
14.
WinstonD.J., BadenL.R., GabrielD.A.Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. Biol Blood Marrow Transplant2006; 12: 635–640.
15.
PayaC., HumarA., DominguezE.Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant2004; 4: 611–620.
16.
MartinD.F., Sierra-MaderoJ., WalmsleyS.A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med2002; 346: 1119–1126.
17.
LenO., GavaldàJ., AguadoJ.M.RESITRA. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients. Clin Infect Dis2008; 46: 20–27.
18.
AyalaE., GreeneJ., SandinR.Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant2006; 37: 851–856.
19.
BuscaA., de FabritiisP., GhisettiV.Oral valganciclovir as pre-emptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation. Transpl Infect Dis2007; 9: 102–107.
20.
van der HeidenP.L., KalpoeJ.S., BargeR.M., WillemzeR., KroesA.C., SchippersE.F.Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant2006; 37: 693–698.
21.
VolinL., BarkholtL., NihtinenA.An open-label randomised study of oral valganciclovir versus intravenous ganciclovir for pre-emptive therapy of cytomegalovirus. Bone Marrow Transplant2008; 39Suppl 1: S47.
22.
LjungmanP., GriffithsP., PayaC.Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis2002; 34: 1094–1097.
23.
GernaG., RevelloM.G., PercivalleE., MorinaF.Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia. J Clin Microbiol1992; 30: 1232–1237.
24.
MonforteV., LopezC., SantosF.A multicenter study of valganciclovir prophylaxis up to day 120 in CMV-seropositive lung transplant recipients. Am J Transplant2009; 9: 1134–1141.
25.
DevyatkoE., ZuckermannA., RuzickaM.Pre-emptive treatment with oral valganciclovir in management of CMV infection after cardiac transplantation. J Heart Lung Transplant2004; 23: 1277–1282.
26.
SinghN., WannstedtC., KeyesL., GayowskiT., WagenerM.M., CacciarelliT.V.Efficacy of valganciclovir administered as pre-emptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation2005; 79: 85–90.
27.
AntinJ.H.Long-term care after hematopoietic-cell transplantation in adults. N Engl J Med2002; 347: 36–42.
28.
LeatherH.L., MeyerC.L., WindgardJ.R.Oral valganciclovir for pre-emptive therapy of cytomegalovirus antigenemia in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant2003; 9: 132.
29.
AlliceT., BuscaA., LocatelliF., FaldaM., PittalugaF., GhisettiV.Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogeneic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus. J Antimicrob Chemother2009; 63: 600–608.
30.
CandoniA., SimeoneE., TiribelliM., PipanC., FaninR.What is the optimal dosage of valganciclovir as pre-emptive therapy for CMV infection in allogeneic hematopoietic SCT?Bone Marrow Transplant2008; 42: 207–208.
